Canadian Cancer Trials Group Bulletins


Clinical Trials Committee

During the Fall 2009 Clinical Trials Committee Teleconference, one trial was approved for activation.

This trial -- A phase III trial of 6 vs 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer -- was presented by the Gastrointestinal Site Committee. The lead groups are CALGB and SWOG.

The primary objective of this study is to compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.

When this trial is centrally activated, notification will be provided in the Bulletin.